Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 50S ribosomal subunit is the larger component of the 70S ribosome found in bacteria and the apicoplast organelle of apicomplexan parasites such as Plasmodium falciparum (Dahl & Rosenthal, 2007, Antimicrobial Agents and Chemotherapy). It is a complex ribonucleoprotein assembly responsible for the peptidyl transferase activity that catalyzes peptide bond formation and contains the exit tunnel through which the nascent polypeptide chain emerges (NCBI Bookshelf, 'The Ribosome'). Because the apicoplast is an essential organelle of endosymbiotic bacterial origin, its translation machinery is highly conserved with bacterial systems and distinct from the human 80S cytosolic ribosome. This structural divergence allows for the selective targeting of pathogens by several classes of antimicrobial agents, including macrolides, lincosamides, and oxazolidinones (StatPearls, 'Macrolides'). In malaria treatment, drugs targeting the apicoplast 50S subunit often exhibit a 'delayed death' effect, where the parasite's progeny are unable to survive due to the loss of apicoplast function in the second generation (Botté et al., 2012, Genes & Development). However, the structural similarity between the 50S subunit and human mitochondrial ribosomes can lead to off-target effects and clinical toxicity, such as myelosuppression or lactic acidosis, during prolonged treatment (Wilson, 2014).
Inhibition of protein synthesis by binding to the 50S ribosomal subunit, which blocks the peptidyl transferase center (PTC) or the ribosomal exit tunnel, thereby preventing peptide bond formation or the translocation of the nascent peptide chain (Wilson, 2014, Nature Reviews Microbiology).
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 50S ribosomal subunit (50S subunit).